Get started
Author

Pat Whitworth

Observed names: P Whitworth, P. Whitworth
OpenAlex ID: A5081516429
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data
2025 · Adam M Brufsky, Kent F Hoskins, et al. · JNCI Cancer Spectrum · 12
PDF
Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline.
2024 · Joyce O'Shaughnessy, Cathy Lynne Graham, et al. · Journal of Clinical Oncology · 9
PDF
Abstract PD9-08: ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database
2023 · Adam M. Brufsky, Midas Kuilman, et al. · Cancer Research · 3
Abstract P2-08-12: Prediction of Chemotherapy Benefit by MammaPrint® in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
2025 · Adam Brufsky, Kent Hoskins, et al. · Clinical Cancer Research · 1
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King
2025 · Rakhshanda Layeequr Rahman, Alfredo Santillan, et al. · International Journal of Molecular Sciences · 1
PDF
Abstract PO5-15-04: MammaPrint index predicts neoadjuvant chemosensitivity in patients with HR+HER2- early-stage breast cancer in the real-world evidence FLEX study
2024 · Joyce O'Shaughnessy, Lajos Pusztai, et al. · Cancer Research · 1
Validation of a multi-omic biosignature for locoregional recurrence and radiation therapy benefit in breast cancer
2026 · Gregory Bruce Mann, Karuna Mittal, et al. · npj Breast Cancer
PDF
Validation of a Multi-Omic Biosignature in a Multi-Institutional Cohort to Predict Locoregional Recurrence Risk and Differential RT Effect in Early-Stage Invasive Breast Cancer
2026 · A.J. Khan, G.B. Mann, et al. · International Journal of Radiation Oncology*Biology*Physics
Tyrer–Cuzick Lifetime Risk Is Not Associated With Non‐BRCA1/2 Pathogenic Variants for Breast Carcinoma
2026 · Divya Rao, Chloe Wernecke, et al. · The Breast Journal
PDF
Abstract P1-11-24: Neoadjuvant Chemotherapy for T3 tumors in the Era of Precision Medicine - Biology is Still King
2025 · Rakhshanda Rahman, Laura Lee, et al. · Clinical Cancer Research
Abstract PD14-05: PD14-05 Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women
2023 · Brent Mabey, Elisha Hughes, et al. · Cancer Research
Abstract P5-08-15: Reducing Rates of Chronic Breast Cancer Related Lymphedema with Screening & Early Intervention: An Update of Recent Data
2023 · Pat Whitworth, Frank Vicini, et al. · Cancer Research
Abstract P3-05-44: Genomic testing and Ki-67 Percentage: Two puzzle pieces being undervalued in breast cancer treatment
2023 · Chloe Wernecke, Krista Ortega, et al. · Cancer Research
Abstract P3-05-43: Germline Testing Results in Patients with Genomic Tumor Profiling
2023 · Peter Beitsch, Chloe Wernecke, et al. · Cancer Research
Abstract P6-02-09: Racial/Ethnic Groups Have Different Rates of Pathogenic Variants in Common Cancer Genes
2023 · Peter Beitsch, Chloe Wernecke, et al. · Cancer Research
OT2-03-02: Prospective Neo-Adjuvant Registry Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry – Symphony Trial (NBRST).
2011 · P Whitworth, P Beitsch, et al. · Cancer Research
Works count: 16
Citation count: 27
H-index: 3
I10-index: 1
Year
Topic
Type